Vaccination against COVID-19: a challenge in CLL
- PMID: 34110406
- PMCID: PMC8192082
- DOI: 10.1182/blood.2021011935
Vaccination against COVID-19: a challenge in CLL
Keywords: CLL; COVID-19; NEOPLASIA/lymphoid leukemias; vaccination.
Conflict of interest statement
Conflict-of-interest disclosure: B.E. received honoraria, participated in advisory boards, or received research grants from the following companies: Abbvie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Gilead, Hexal, Janssen, MSD, Novartis, Oxford Biomedica, Pharmacyclics, and Roche. ▪
Figures
Comment on
-
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.Blood. 2020 Oct 8;136(15):1786-1789. doi: 10.1182/blood.2019004685. Blood. 2020. PMID: 32492706 Free PMC article.
-
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568. Blood. 2021. PMID: 33861303 Free PMC article.
References
-
- Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737-746. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
